Literature DB >> 20231400

Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection.

Nina Thakkar1, Vanessa Pirrone, Shendra Passic, Shawn Keogan, Wei Zhu, Vladyslav Kholodovych, William Welsh, Robert Rando, Mohamed Labib, Brian Wigdahl, Fred C Krebs.   

Abstract

We previously demonstrated that the biguanide-based compound NB325 inhibits human immunodeficiency virus type 1 (HIV-1) infection by interacting with the CXCR4 viral coreceptor. This interaction also appeared to be persistent, since HIV-1 infection was inhibited even when the virus was introduced subsequent to the removal of NB325 from the cell culture medium. The present studies were conducted to determine the extent and mechanism of this prolonged antiviral activity. Persistent inhibition of HIV-1 infection by NB325 was concentration dependent and was apparent up to 8 h after removal of the compound. Flow cytometric analyses of stimulated CD4(+) T lymphocytes exposed to NB325 demonstrated concentration-dependent reductions in CXCR4 extracellular loop 2 epitope recognition that were maintained up to 24 h after removal of the compound. CXCL12-induced chemotaxis was also persistently inhibited following pre-exposure to NB325. These results demonstrate that persistent inhibition of X4 HIV-1 infection by NB325 involves extended perturbation of the viral coreceptor CXCR4.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231400      PMCID: PMC2863618          DOI: 10.1128/AAC.00934-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.

Authors:  P Greenhead; P Hayes; P S Watts; K G Laing; G E Griffin; R J Shattock
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

4.  A study of the antibacterial activity of some polyhexamethylene biguanides towards Escherichia coli ATCC 8739.

Authors:  P Broxton; P M Woodcock; P Gilbert
Journal:  J Appl Bacteriol       Date:  1983-06

5.  A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.

Authors:  Dimitrios Motakis; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Injury and recovery of Escherichia coli ATCC 8739 from treatment with some polyhexamethylene biguanides.

Authors:  P Broxton; P M Woodcock; P Gilbert
Journal:  Microbios       Date:  1984

7.  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

Authors:  Yven Van Herrewege; Guido Vanham; Jo Michiels; Katrien Fransen; Luc Kestens; Koen Andries; Paul Janssen; Paul Lewi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Lynn R Budgeon; Elizabeth B Neely; Maelee Ferguson; Fred C Krebs; Mary K Howett; Mohamed Labib; Robert Rando; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Interaction of a polymeric biguanide biocide with phospholipid membranes.

Authors:  T Ikeda; A Ledwith; C H Bamford; R A Hann
Journal:  Biochim Biophys Acta       Date:  1984-01-11

10.  In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

Authors:  Yven Van Herrewege; Jo Michiels; Jens Van Roey; Katrien Fransen; Luc Kestens; Jan Balzarini; Paul Lewi; Guido Vanham; Paul Janssen
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  7 in total

Review 1.  Metformin and other biguanides in oncology: advancing the research agenda.

Authors:  Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-01

2.  Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.

Authors:  Royce A Wilkinson; Seth H Pincus; Joyce B Shepard; Sarah K Walton; Edward P Bergin; Mohamed Labib; Martin Teintze
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

3.  Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.

Authors:  Shendra R Passic; Mary Lee Ferguson; Bradley J Catalone; Tina Kish-Catalone; Vladyslav Kholodovych; Wei Zhu; William Welsh; Robert Rando; Mary K Howett; Brian Wigdahl; Mohamed Labib; Fred C Krebs
Journal:  Biomed Pharmacother       Date:  2010-11-04       Impact factor: 6.529

4.  Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.

Authors:  Karissa Lozenski; Tina Kish-Catalone; Vanessa Pirrone; Robert F Rando; Mohamed Labib; Brian Wigdahl; Fred C Krebs
Journal:  J Biomed Biotechnol       Date:  2011-10-24

5.  Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.

Authors:  Shawn Keogan; Shendra Passic; Fred C Krebs
Journal:  Int J Pept       Date:  2012-01-29

6.  Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Fred C Krebs
Journal:  Virol J       Date:  2012-01-26       Impact factor: 4.099

7.  Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review).

Authors:  Steven Lehrer
Journal:  World Acad Sci J       Date:  2020-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.